Der Browser den Sie verwenden ist sehr alt.

Wir können daher nicht sicherstellen, dass jede Funktion (Gestaltung, Bilder und zusätzliche Funktionen) dieser Internetseite im vollen Umfang zur Verfügung steht. Bitte nutzen Sie eine aktuellere Browserversion.
Wir bitten um Ihr Verständnis.
Startseite > Forschung > Wissenschaftliche Originalarbeiten > 2008

Wissenschaftliche Originalarbeiten 2008

  1. Banat M, Lüke M, Siapich SA, Hescheler J, Weiergräber M, Schneider T (2008) The dihydropyrine isradipine inhibits the murine but not the bovine A-wave response of the electroretinogram. Acta Ophthalmol 86: 676-82
  2. Beutel J, Lüke M, Bartz-Schmidt KU, Grisanti S (2008) Vitreal-induced RPE cell traction: Investigation of pathological vitreous samples in an in vitro contraction model. Ophthalmologe (Epub ahead of print)
  3. Beutel J, Ziemssen F, Lüke M, Partsch M, Bartz-Schmidt KU, The Bevacizumab Study Group, Gelisken F (2008) Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: One-year results. Int J Ophthalmol (Epub ahead of print)
  4. Beutel S, Peters S, Lüke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E, the Bevacizumab Study Group, Grisanti S (2008) Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmologica (Epub ahead of print)
  5. Brüggemann A, Hoerauf H (2008) Atypische Makulaforamina nicht idiopathischer Genese. Klin Monatsbl Augenheilkd 225: 281-285
  6. Brüggemann A (2008) Gesucht - gefunden: Eine Literaturrecherche über die altersbedingte Makuladegeneration. Z prakt Augenheilkd 29: 428
  7. Brüggemann A, Noltze A, Lange T, Kaun M, Gliemroth J, Goerg S, Bahlmann L, Klaus S, Siemers F, Mailänder P, Machens HG (2008) Significant c3a increase in free flaps after prolonged ischemia. J Surg Res Mar 26
  8. Geerling G, Unterlauft JD, Kasper K, Schrader S, Opitz A, Hartwig D (2008) Autologous serum and alternative blood products for the treatment of ocular surface disorders. Ophthalmologe 105: 623-631
  9. Grisanti S, Tatar O (2008) The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 372-390
  10. Grisanti S, Altvater A, Peters S (2008) Safety parameters for indocyanine green in vitreoretinal surgery. Dev. Ophthalmol 42: 43-68
  11. Harloff S, Hartwig D, Kasper K, Wedel T, Müller M, Geerling G (2008) Epitheliotrophe Kapazität von Serum-Augentropfen
    gesunder versus immunsupprimierter Patienten mit rheumatoider Arthritis. Klin Monatsbl Augenheilkd 225: 200-206
  12. Kusserow C, Müller M (2008) 40 Jahre inkomplette Silikonöltamponade nach Ablatiochirurgie. Klin Monatsbl Augenheilkd 25: 298-301
  13. Kutta H, Willer A, Steven P, Bräuer L, Tsokas M, Paulsen F (2008) Distribution of mucins and antimicrobial substances lysozyme and lactoferrin in the laryngeal subglottic region. J Anat Oct. 213(4): 473-481
  14. Lüke M, Januschowski K, Beutel J, Warga M, Grisanti S, Peters S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P (2008) The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 87: 22-29
  15. Lüke C, Dietlein TS, Lüke M, Konen W, Krieglstein GK (2008) A prospective trial of phaco-trabeculotomy combined with deep sclerectomy versus phaco-trabeculectomy. Graefe`s Arch Clin Exp Ophthalmol 246: 1163-8
  16. Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Jaissle GB, Bartz-Schmidt KU, Szurman P (2008) Electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina. Graefe`s Arch Clin Exp Ophthalmol 245: 817-22
  17. Machner B, Neppert B, Paulsen M, Hofmann C, Sander T, Helmchen C (2008) Pseudotumor cerebri as a reversible side effect of all-trans retinoic acid (ATRA) treatment in acute promyelocytic laukaemia. Eur J Neurol 15: 68-69
  18. Menke T, Neppert B (2008) Morgens beidseitige Visusminderung, abends kardiologische Intensivstation. Ophthalmologe 105: 584-7
  19. Müller M, Hoerauf H, Geerling G (2008) Prof. Dr. Horst Laqua zum 65. Geburtstag - Der Blick für das Wesentliche.
    Klin Monatsbl Augenheilkd 225: 192-193
  20. Müller M, Geerling G (2008) Optische Kohärenztomographie des vorderen Augenabschnittes bei Glaukom.
    Klin Monatsbl Augenheilkd 225: 194-199
  21. Müller M, Kusserow C, Orth U, Klär-Dißars U, Laqua H, Gal A (2008) Mutationen des Frizzled-4-Gens. Ihre Bedeutung in der Betreuung von Familien mit autosomal-dominanter exsudativer Vitreoretinopathie. Ophthalmologe 105: 262-268
  22. Müller M (2008) Use of MICS in combined surgery. MICS Platform Expert Newsletter, 7: 3
  23. Paulsen FP, Woon CW, Varoga D, Jansen A, Garreis F, Jäger K, Amm M, Podolsky DK, Steven P, Barker NP, Sel S (2008) Intestinal Trefoil Factor / TFF3 promotes re-epithelialization of corneal wounds. J Biol Chem 283: 13418-13427
  24. Peters S, Ziemssen F, Grisanti S (2008) Die Behandlung von ophthalmologischen Erkrankungen - Neue medikamentöse Ansätze. Internistische Praxis 48: 205-211
  25. Peters S, Heiduschka P, Julien S, Bartz-Schmidt KU, Schraermeyer U (2008) Immunohistochemical localization of intravitreally injected bevacizumab in the anterior chamber angle, iris and ciliary body of the primate eye. Br J Ophthalmol 92: 541-544
  26. Peters S, Ziemssen F, Grisanti S (2008) Ophthalmologische Erkrankungen. Neue medikamentöse Ansätze. Arzneimittel, Therapie - Kritik & Medizin und Umwelt 40:  69-75
  27. Peters S, Heiduschka P, Bartz-Schmidt KU, Schraermeyer U (2008) Penetration of Bevacizumab into the iris, anterior chamber angle and ciliary body after intravitreal injection. Eur Ophthalmic Review (in press)
  28. Rudolf M, Malek G, Messinger JD, Clark ME, Wang L, Curcio CA (2008) Sub-retinal drusenoid deposits in human retina: Organization and composition. Exp Eye Res 87: 402-408
  29. Rudolf M, Clark ME, Chimento MF, Li CM, Medeiros NE, Curcio CA (2008) Prevalence and morphology of druse types in the macula and periphery of eyes with age-related maculopathy. Invest Ophthalmol Vis Sci 49: 1200-9
  30. Schmidt-Erfurth U, Rudolf M, Funk M, Hofmann-Rummelt C, Franz-Haas NS, Aherrahrou Z, Schlötzer-Schrehardt U (2008) Ultrastructural changes in a murine model of graded Bruch membrane lipoidal degeneration and corresponding VEGF 164 detection. Invest Ophthalmol Vis Sci 49: 390-8
  31. Schrader S, Neppert B (2008) Leber`sche hereditäre Optkusneuropathie (LHON) bei initialem Verdacht auf Neuritis nervi optici. Klin Monatsbl Augeheilkd 25: 302-303
  32. Schrader S, Mircheff AK, Geerling G (2008) Animal models of dry eye. Dev Ophthalmol 41: 298-312
  33. Sprenger A, Neppert B, Köster S, Grais S, Kömpf D, Helmchen C, Kimmig H (2008) Long-term eye movement recordings with a scleral search coil-eyelid protection device allows new applications. Short communication. J Neurosc Methods 170: 305-309
  34. Spitzer MS, Yoeruek E, Kaczmarek RT, Sierra A, Aisenbrey S, Grisanti S, Bartz-Schmidt KU, Szurman P (2008) Sodium hyaluronate gels as a drug-release system for corticosteroids: release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol 86: 842-8
  35. Steven P, Klinger M, Hoerauf H (2008) Bilaterale pigmentierte epi- und subretinale Membran. Klin Monatsbl Augenheilkd 225: 240-242
  36. Steven P, Rupp J, Hüttmann G, Koop N, Lensing C, Laqua H, Gebert A (2008) Experimental induction and three-dimensional two-photon imaging of conjunctiva-associated lymphoid tissue. Invest Ophthalmol Vis Sci 49 (4): 1512-7
  37. Steven P, Koop N, Hüttmann G (2008) Confocal microscopy versus two-photon microscopy: imaging of ocular surface pathologies. Proc. SPIE 6860 686022 Febr. 15, 2008
  38. Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU, for The Tuebingen Bevacizumab Study Group, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, Pertile G, Scharioth GB, Grisanti S (2008) Effect of Bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 126: 782-790
  39. Tatar O, Shinoda K, Kaiserling E, Pertile G, Eckardt C, Mohr A, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S (2008) Early effects of triamcinolone on vascular endothelial growth factor and endostatin in human chorioidal neovascularization. Arch Ophthalmol 126: 193-199
  40. Tatar O et al. (2008) Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human chorioidal neovascularization. Arch Ophthalmol 127: 275-281
  41. Ulmer A, Beutel J, Süsskind D, Hilgers R-D, Ziemssen F, Lüke M, Röcken M, Rohrbach M, Fierlbeck G, Bartz-Schmidt K-U, Grisanti S (2008) Visualization of circulating melanoma cells in peripheral blood of patients with primary uveal melanoma. Clin Cancer Res 14: 4469-74
  42. Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P (2008) Toxic effects of recombinant tissue plasminogen activator on cultured human corneal endothelial cells. Invest Ophthalmol Vis Sci 49: 1392-7
  43. Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P; Tübingen Bevacizumab Study Group (2009) Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovasularization after chemical burn. Acta Ophthalmol 86: 322-8
  44. Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Tübingen Bevacizumab Study Group, Grisanti S (2008) Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 115: 1750-55
  45. Ziemssen F, Lüke M, Bartz-Schmdit KU, Gelisken F (2008) Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective randomized pilot trial of photodynamic therapy versus full macular translocation). Graefe`s Arch Clin Exp Ophthalmol 246: 653-9
  46. Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU, Tuebingen Bevacizumab Study Group (2008) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical  (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroup of patients. Int Ophthalmol 28:101-109
  47. Ziemssen F, Heiduschka P, Peters S, Grisanti S, Schraermeyer U (2008) Chances and risks of anti-VEGF therapy. Klin Monatsbl Augenheilkd 225: 770-778
  48. Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group, Ziemssen T (2008) Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2008, April 17 (Epub ahead of print)